Bristol-Myers Squibb Company (ETR:BRM)
Germany · Delayed Price · Currency is EUR | Market Cap | 94.33B -14.4% |
| Revenue (ttm) | 40.94B +1.3% |
| Net Income | 5.15B |
| EPS | 2.53 |
| Shares Out | n/a |
| PE Ratio | 18.33 |
| Forward PE | 9.54 |
| Dividend | 2.15 (4.65%) |
| Ex-Dividend Date | Jan 2, 2026 |
| Volume | 2,112 |
| Average Volume | 2,434 |
| Open | 46.31 |
| Previous Close | 46.31 |
| Day's Range | 46.15 - 46.53 |
| 52-Week Range | 36.60 - 58.79 |
| Beta | 0.30 |
| RSI | 50.36 |
| Earnings Date | Feb 5, 2026 |
About ETR:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
Victory Growth and Tax Strategy Fund Buys 9,683 Shares of Bristol-Myers Squibb Co (BMY)
Victory Growth and Tax Strategy Fund Buys 9,683 Shares of Bristol-Myers Squibb Co (BMY)
Putnam Dynamic Asset Allocation Equity Fund Buys 129 Shares of Bristol-Myers Squibb Co (BMY)
Putnam Dynamic Asset Allocation Equity Fund Buys 129 Shares of Bristol-Myers Squibb Co (BMY)
Putnam Multi-Asset Income Fund Buys 115 Shares of Bristol-Myers Squibb Co (BMY)
Putnam Multi-Asset Income Fund Buys 115 Shares of Bristol-Myers Squibb Co (BMY)
Bristol-Myers Squibb (BMY) Sees Price Target Raised by Piper Sandler | BMY Stock News
Bristol-Myers Squibb (BMY) Sees Price Target Raised by Piper Sandler | BMY Stock News
Bristol Myers Squibb (BMY) Exec Joins Pacira BioSciences Board
Bristol Myers Squibb (BMY) Exec Joins Pacira BioSciences Board
Bristol-Myers Squibb (BMY) Leads Record Lobbying Surge in Healthcare
Bristol-Myers Squibb (BMY) Leads Record Lobbying Surge in Healthcare
MASTERINVEST Kapitalanlage GmbH Sells 11,221 Shares of Bristol-Myers Squibb Co (BMY)
MASTERINVEST Kapitalanlage GmbH Sells 11,221 Shares of Bristol-Myers Squibb Co (BMY)
WBH ADVISORY INC Buys 4,407 Shares of Bristol-Myers Squibb Co (BMY)
WBH ADVISORY INC Buys 4,407 Shares of Bristol-Myers Squibb Co (BMY)
Transcendent Capital Group LLC Buys 5,897 Shares of Bristol-Myers Squibb Co (BMY)
Transcendent Capital Group LLC Buys 5,897 Shares of Bristol-Myers Squibb Co (BMY)
LUTS & GREENLEIGH GROUP, INC. Buys 3,950 Shares of Bristol-Myers Squibb Co (BMY)
LUTS & GREENLEIGH GROUP, INC. Buys 3,950 Shares of Bristol-Myers Squibb Co (BMY)
LEDERER & ASSOCIATES INVESTMENT COUNSEL/CA Sells 19,787 Shares of Bristol-Myers Squibb Co (BMY)
LEDERER & ASSOCIATES INVESTMENT COUNSEL/CA Sells 19,787 Shares of Bristol-Myers Squibb Co (BMY)
Main Street Group, LTD Sells 682 Shares of Bristol-Myers Squibb Co (BMY)
Main Street Group, LTD Sells 682 Shares of Bristol-Myers Squibb Co (BMY)
Patriot Financial Group Insurance Agency, LLC Buys 4,107 Shares of Bristol-Myers Squibb Co (BMY)
Patriot Financial Group Insurance Agency, LLC Buys 4,107 Shares of Bristol-Myers Squibb Co (BMY)
AE Wealth Management LLC Buys 400,922 Shares of Bristol-Myers Squibb Co (BMY)
AE Wealth Management LLC Buys 400,922 Shares of Bristol-Myers Squibb Co (BMY)
What the Options Market Tells Us About Bristol-Myers Squibb
Financial giants have made a conspicuous bullish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb (NYSE: BMY) revealed 9 unusual trades. Delving into the details...
San Luis Wealth Advisors LLC Buys 4,185 Shares of Bristol-Myers Squibb Co (BMY)
San Luis Wealth Advisors LLC Buys 4,185 Shares of Bristol-Myers Squibb Co (BMY)
INVESTED ADVISORS Buys 1,638 Shares of Bristol-Myers Squibb Co (BMY)
INVESTED ADVISORS Buys 1,638 Shares of Bristol-Myers Squibb Co (BMY)
BCS Wealth Management Buys 5,221 Shares of Bristol-Myers Squibb Co (BMY)
BCS Wealth Management Buys 5,221 Shares of Bristol-Myers Squibb Co (BMY)
Notable healthcare headlines for the week: J&J, Moderna, Bristol Myers in focus
S&P 500 healthcare weekly update: top gainers/losers and key news on J&J earnings, GSK-RAPT deal, AI lung cancer pact, and UNH rebates—Read now.
Bristol Myers Squibb: The Rerating Was Fast - The Proof Will Be Slow (Rating Downgrade)
Goldman Sachs Strategic Factor Allocation Fund Buys 34,509 Shares of Bristol-Myers Squibb Co (BMY)
Goldman Sachs Strategic Factor Allocation Fund Buys 34,509 Shares of Bristol-Myers Squibb Co (BMY)
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion
VICUS CAPITAL Buys 4,387 Shares of Bristol-Myers Squibb Co (BMY)
VICUS CAPITAL Buys 4,387 Shares of Bristol-Myers Squibb Co (BMY)
Paragon Capital Management Ltd Buys 4,129 Shares of Bristol-Myers Squibb Co (BMY)
Paragon Capital Management Ltd Buys 4,129 Shares of Bristol-Myers Squibb Co (BMY)
True North Advisors, LLC Sells 12,530 Shares of Bristol-Myers Squibb Co (BMY)
True North Advisors, LLC Sells 12,530 Shares of Bristol-Myers Squibb Co (BMY)